Skip to main content

Table 1 Selected studies with CRS and HIPEC in patients with peritoneal carcinomatosis of different origin.

From: Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Author, year

n

Tumor entity

Cytostatic agent(s)

Morbidity

Mortality

Median survival

Overall survival

Survival

CCR-0/1

    

[%]

[%]

[months]

[%]

[%]

Verwaal, 2003[25, 41]

105

CRC

MMC

35

8

22

28 (3-y)

45 (5-y)

Glehen, 2004[33]

506

CRC

MMC/LOHP

23

4

19

39 (3-y)

47 (3-y)

Shen, 2004[34]

77

CRC

MMC

30

12

16

25 (3-y)

44 (3-y)

Glehen, 2004[29]

49

GC

MMC

27

4

10

8 (5-y)

29 (5-y)

Hall, 2004[45]

34

GC

MMC

35

0

11

-

21 (5-y)

Yonemura, 2005[30]

105

GC

MMC/DDP

22

3

19

7 (5-y)

27 (5-y)

Feldmann, 2003[35]

49

DMPM

DDP

25

0

92

59 (5-y)

-

Deraco, 2006[36]

49

DMPM

DDP/DXR

DDP/MMC

27

0

-

57 (5-y)

-

Yan, 2007[27]

70

DMPM

DDP/DXR

36

3

59

49 (5-y)

-

Piso, 2004[37]

19

OC

DDP; MITO

28

5

33

15 (5-y)

44 (5-y)

Cotte, 2007[38]

81

OC

DDP

14

3

28

-

-

Di Giorgio, 2008[26]

47

OC

DDP

21

4

30

17 (5-y)

26 (5-y)

  1. CRC: colorectal cancer, GC: gastric cancer, PMP: pseudomyxoma peritonei, OC: ovarian cancer, DMPM: diffuse malignant peritoneal mesothelioma, MMC: mitomycin C, DDP: cisplatin, LOHP: oxaliplatin, DXR: doxorubicin, MITO: mitoxantrone